$RGLS
Regulus Therapeutics Inc.

2016 Q2 Form 10-Q Financial Statement

#000162828016015293 Filed on May 03, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $483.0K $489.0K $4.200M
YoY Change -87.4% -88.36% 157.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.660M $5.100M $3.640M
YoY Change -37.01% 40.11% 33.33%
% of Gross Profit
Research & Development $18.01M $16.76M $13.43M
YoY Change -6.22% 24.85% 39.81%
% of Gross Profit
Depreciation & Amortization $510.0K $419.0K $394.0K
YoY Change 24.39% 6.35% 11.3%
% of Gross Profit
Operating Expenses $21.67M $21.87M $17.07M
YoY Change -13.37% 28.09% 38.38%
Operating Profit -$21.19M -$21.38M -$12.87M
YoY Change 0.03% 66.09% 20.23%
Interest Expense $90.00K $24.00K $8.000K
YoY Change 1185.71% 200.0% -27.27%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.10M -$21.21M -$14.49M
YoY Change 0.29% 46.38% 13.74%
Income Tax -$8.000K -$5.000K -$4.000K
% Of Pretax Income
Net Earnings -$21.09M -$21.21M -$14.49M
YoY Change 0.26% 46.39% 13.7%
Net Earnings / Revenue -4366.46% -4336.81% -344.93%
Basic Earnings Per Share -$0.40 -$0.40 -$0.29
Diluted Earnings Per Share -$4.793M -$4.831M -$3.475M
COMMON SHARES
Basic Shares Outstanding 52.78M shares 52.70M shares 50.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $107.5M $105.1M $148.8M
YoY Change -22.88% -29.37% 29.84%
Cash & Equivalents $27.04M $19.25M $19.60M
Short-Term Investments $80.50M $85.80M $129.2M
Other Short-Term Assets $522.0K $410.0K $4.900M
YoY Change -87.27% -91.63% 40.0%
Inventory
Prepaid Expenses $7.565M $9.272M
Receivables $100.0K $100.0K $4.900M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $116.2M $115.8M $158.5M
YoY Change -19.33% -26.97% 34.08%
LONG-TERM ASSETS
Property, Plant & Equipment $12.32M $10.96M $3.444M
YoY Change 272.27% 218.12% -9.49%
Goodwill
YoY Change
Intangibles $1.062M $1.069M $1.087M
YoY Change -0.93% -1.66% -0.73%
Long-Term Investments
YoY Change
Other Assets $310.0K $354.0K $1.800M
YoY Change -82.72% -80.33% 84.05%
Total Long-Term Assets $13.69M $12.38M $6.331M
YoY Change 121.73% 95.53% 7.71%
TOTAL ASSETS
Total Short-Term Assets $116.2M $115.8M $158.5M
Total Long-Term Assets $13.69M $12.38M $6.331M
Total Assets $129.9M $128.1M $164.8M
YoY Change -13.53% -22.27% 32.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.504M $3.622M $2.677M
YoY Change 45.58% 35.3% -0.52%
Accrued Expenses $5.472M $5.456M $5.318M
YoY Change -19.93% 2.59% 62.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $11.10M $11.01M $14.35M
YoY Change -23.72% -23.27% 49.99%
LONG-TERM LIABILITIES
Long-Term Debt $19.80M $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $8.570M $7.850M $903.0K
YoY Change 965.92% 769.32% -33.65%
Total Long-Term Liabilities $8.570M $7.850M $903.0K
YoY Change 965.92% 769.32% -33.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.10M $11.01M $14.35M
Total Long-Term Liabilities $8.570M $7.850M $903.0K
Total Liabilities $41.48M $20.91M $18.02M
YoY Change 135.19% 16.01% -43.36%
SHAREHOLDERS EQUITY
Retained Earnings -$233.8M -$212.7M -$150.3M
YoY Change 36.5% 41.57% 63.63%
Common Stock $322.3M $320.0M $297.2M
YoY Change 6.01% 7.67% 691160.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.45M $107.2M $146.8M
YoY Change
Total Liabilities & Shareholders Equity $129.9M $128.1M $164.8M
YoY Change -13.53% -22.27% 32.83%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$21.09M -$21.21M -$14.49M
YoY Change 0.26% 46.39% 13.7%
Depreciation, Depletion And Amortization $510.0K $419.0K $394.0K
YoY Change 24.39% 6.35% 11.3%
Cash From Operating Activities -$17.35M -$8.930M -$11.25M
YoY Change 77.58% -20.64% 24.62%
INVESTING ACTIVITIES
Capital Expenditures $130.0K $395.0K $236.0K
YoY Change -176.47% 67.37% 214.67%
Acquisitions
YoY Change
Other Investing Activities $5.170M $12.09M -$7.150M
YoY Change -50.76% -269.09% -31.32%
Cash From Investing Activities $5.300M $11.69M -$7.390M
YoY Change -48.69% -258.2% -29.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $363.0K $257.0K
YoY Change 41.25% -97.36%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.83M $528.0K $915.0K
YoY Change 2055.43% -42.3% -91.01%
NET CHANGE
Cash From Operating Activities -17.35M -$8.930M -$11.25M
Cash From Investing Activities 5.300M $11.69M -$7.390M
Cash From Financing Activities 19.83M $528.0K $915.0K
Net Change In Cash 7.780M $3.289M -$17.73M
YoY Change 425.68% -118.55% 89.98%
FREE CASH FLOW
Cash From Operating Activities -$17.35M -$8.930M -$11.25M
Capital Expenditures $130.0K $395.0K $236.0K
Free Cash Flow -$17.48M -$9.325M -$11.49M
YoY Change 82.08% -18.83% 26.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52781008 shares
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
CY2016Q1 dei Trading Symbol
TradingSymbol
RGLS
CY2016Q1 rgls Short Term Investment Maturity Weighted Average
ShortTermInvestmentMaturityWeightedAverage
P2Y
CY2015Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
10021000 USD
CY2016Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
61000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2717000 USD
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3622000 USD
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-425000 USD
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-198000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6329000 USD
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5456000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-133000 USD
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-92000 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
315673000 USD
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
319990000 USD
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3103000 USD
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3749000 USD
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2813279 shares
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
86000 USD
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2413720 shares
CY2015Q4 us-gaap Assets
Assets
141083000 USD
CY2016Q1 us-gaap Assets
Assets
128138000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
134258000 USD
CY2016Q1 us-gaap Assets Current
AssetsCurrent
115759000 USD
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
98103000 USD
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
85849000 USD
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000 USD
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000 USD
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
103000 USD
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
49000 USD
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
98184000 USD
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
85869000 USD
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37327000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19600000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15960000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19249000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17727000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3289000 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11394504 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52669266 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52774550 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52669266 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52774550 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
53000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14429000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21167000 USD
CY2015Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1356738 shares
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
4.00
CY2012Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5400000.0 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1194000 USD
CY2016Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
723000 USD
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2065000 USD
CY2016Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2047000 USD
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
394000 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
419000 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2392000 USD
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1211000 USD
CY2015Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-50000 USD
CY2016Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3644000 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5103000 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14491000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21212000 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000 USD
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000 USD
CY2015Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
CY2016Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
2469000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-9959000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
471000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
906000 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
899000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-596000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-79000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
87000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-389000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-489000 USD
CY2015Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1059000 USD
CY2016Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1181000 USD
CY2015Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-226000 USD
CY2016Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-338000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
148000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1113000 USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1081000 USD
CY2016Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1069000 USD
CY2015Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
199000 USD
CY2016Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
190000 USD
CY2015Q1 us-gaap Interest Expense
InterestExpense
8000 USD
CY2016Q1 us-gaap Interest Expense
InterestExpense
24000 USD
CY2015Q1 us-gaap Interest Paid
InterestPaid
8000 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
5000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
17005000 USD
CY2016Q1 us-gaap Liabilities
Liabilities
20909000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141083000 USD
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128138000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12632000 USD
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11012000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
915000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
528000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7390000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11691000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11252000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8930000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-14487000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-21207000 USD
CY2015Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-1800000 USD
CY2015Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-1811000 USD
CY2016Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
0 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
17071000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
21867000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12871000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21378000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
759000 USD
CY2016Q1 us-gaap Other Assets Current
OtherAssetsCurrent
410000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
344000 USD
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
354000 USD
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000 USD
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2308000 USD
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7850000 USD
CY2015Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
0 USD
CY2016Q1 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
5470000 USD
CY2015Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
7000 USD
CY2016Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
11000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
395000 USD
CY2015Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
37157000 USD
CY2016Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
20475000 USD
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8159000 USD
CY2016Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9272000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
257000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
363000 USD
CY2015Q1 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
0 USD
CY2016Q1 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-338000 USD
CY2015Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
30010000 USD
CY2016Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
32572000 USD
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
695000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
206000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5400000 USD
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10956000 USD
CY2015Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
37000 USD
CY2016Q1 us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
41000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13427000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16764000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1256000 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
918000 USD
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1400000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-191515000 USD
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212722000 USD
CY2015Q1 us-gaap Revenues
Revenues
4200000 USD
CY2016Q1 us-gaap Revenues
Revenues
489000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3103000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3749000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
419000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.61
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1960000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5126000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6624083.000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6624083 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.91
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.19
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.83
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.75
CY2015Q1 us-gaap Share Price
SharePrice
18.58
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
98103000 USD
CY2016Q1 us-gaap Short Term Investments
ShortTermInvestments
85849000 USD
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
43000 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
124078000 USD
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
107229000 USD
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50071165 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52710672 shares
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001628280-16-015293-index-headers.html Edgar Link pending
0001628280-16-015293-index.html Edgar Link pending
0001628280-16-015293.txt Edgar Link pending
0001628280-16-015293-xbrl.zip Edgar Link pending
ex-10320160331.htm Edgar Link pending
ex-31120160331.htm Edgar Link pending
ex-312x20160331.htm Edgar Link pending
ex-321x20160331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20160331.xml Edgar Link completed
rgls-20160331.xsd Edgar Link pending
rgls-20160331_cal.xml Edgar Link unprocessable
rgls-20160331_def.xml Edgar Link unprocessable
rgls-20160331_lab.xml Edgar Link unprocessable
rgls-20160331_pre.xml Edgar Link unprocessable
rgls20160331-10q.htm Edgar Link pending
Show.js Edgar Link pending